AXSM - Citi starts Axsome at buy calls it top pick for 2024
2023-12-13 14:55:30 ET
More on Axsome Therapeutics
- Axsome Therapeutics: Positive Q3, We Like The Launch Success Story
- Axsome Therapeutics: Costs Outpacing Auvelity Growth (Rating Downgrade)
- Axsome Therapeutics, Inc. (AXSM) Q3 2023 Earnings Call Transcript
- Axsome Therapeutics GAAP EPS of -$1.32 misses by $0.09, revenue of $57.79M beats by $2.93M
- Axsome Therapeutics Q3 2023 Earnings Preview
For further details see:
Citi starts Axsome at buy, calls it top pick for 2024